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Abstract

Immune activation associated with HIV-1 infection contributes to morbidity and mortality. We studied whether
chloroquine, through Toll-like receptor (TLR) antagonist properties, could reduce immune activation thought to
be driven by TLR ligands, such as gut-derived bacterial elements and HIV-1 RNAs. AIDS Clinical Trials Group
A5258 was a randomized, double-blind, placebo-controlled study in 33 HIV-1-infected participants off antiretroviral therapy (ART) and 37 participants on ART. Study participants in each cohort were randomized 1:1 to
receive chloroquine 250 mg orally for the first 12 weeks then cross over to placebo for 12 weeks or placebo first
and then chloroquine. Combining the periods of chloroquine use in both arms of the on-ART cohort yielded a
modest reduction in the proportions of CD8 T cells co-expressing CD38 and DR (median decrease = 3.0%,
p = .003). The effect on immune activation in the off-ART cohort was likely confounded by increased plasma
HIV-1 RNA during chloroquine administration (median 0.29 log10 increase, p < .001). Transcriptional analyses
in the off-ART cohort showed decreased expression of interferon-stimulated genes in 5 of 10 chloroquinetreated participants and modest decreases in CD38 and CCR5 RNAs in all chloroquine-treated participants.
Chloroquine modestly reduced immune activation in ART-treated HIV-infected participants. Clinical Trials
Registry Number: NCT00819390.

Introduction

C

hronic HIV infection is characterized by increased
immune activation,1–3 lymphocyte turnover,1,4 and
heightened expression of inflammatory cytokines.5 Immune
activation predicts clinical outcome in natural history studies,6–8 and inflammatory indices are linked to morbidity,
mortality, and failure to restore circulating CD4 T-cell counts

in individuals receiving antiretroviral therapy (ART).9–11
Immune activation and inflammation decrease, but do not
completely normalize, when viral suppression is achieved
after administration of ART.12,13 The drivers of persistent
activation and inflammation in treated HIV infection are not
known but plausible candidates include HIV, other copathogens such as cytomegalovirus, and translocation of
microbial products from the damaged gut.14,15
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CHLOROQUINE AND HIV IMMUNE ACTIVATION

Toll-like receptors (TLRs), a family of transmembrane
microbial sensors expressed on a variety of cell types,16–18
arm innate defenses and, when ligated, can result in immune
activation and inflammation. TLRs recognizing microbial
surface components are typically expressed on the cell surface; TLRs recognizing microbial nucleic acids are typically
expressed in the endosomal compartment.18
Chloroquine, initially developed as an antimalarial agent,
has immunomodulatory properties useful in the treatment of
autoimmune diseases such as systemic lupus erythematosus
and rheumatoid arthritis.19,20 In both in vitro and in vivo
experimental models, chloroquine inhibits proinflammatory
cytokine release induced by microbial TLR ligands by
downregulating TLR9 and TLR4 mRNA expression, blocking NFjB and activated protein-1 activation, interrupting
endosome maturation,21 and inhibiting nucleic acid binding
to TLR7, 8, and 9.22 When given to individuals with autoimmune disease, chloroquine decreased the numbers of activated HLA-DR+ cells in the skin of those with systemic
lupus erythematosus23 and reduced the elevated levels of the
proinflammatory cytokines, interleukin (IL)-6, IL-18, and
tumor necrosis factor-a in plasma.23
We investigated whether chloroquine administration could
reduce the immune activation in HIV infection posited to be
driven by microbial TLR ligands.
Materials and Methods
Study design

AIDS Clinical Trials Group A5258 was a randomized,
double-blind, placebo-controlled study comparing 12 weeks of
chloroquine to placebo administration for effects on immune
activation in two sequential cohorts of HIV-infected individuals: off-ART (cohort 1: arms A and B) and on-ART (cohort 2:
arms C and D). Eligible participants were aged 18–55 (cohort
1) (taking no ART for at least 6 months before study entry,
with plasma HIV-1 RNA levels ‡1,000 copies/ml and CD4 Tcell counts ‡400 cells/mm3 (off-ART) or (cohort 2) taking
ART for at least 24 months before entry, with CD4+ T-cell
counts <350 cells/mm3 and plasma HIV-1 RNA levels below
the limit of detection using clinical assays (on-ART).
Study participants in each cohort were randomized 1:1 to
receive chloroquine 250 mg orally for the first 12 weeks and
then to cross over to placebo for 12 weeks (arms A and C) or
placebo for 12 weeks then cross over to chloroquine 250 mg
for 12 weeks (arms B and D). The design allowed (1) comparison of week 12 change from baseline between arms A and
B (off-ART) and between arms C and D (on-ART) and (2)
assessment of changes after 12 weeks of chloroquine in both
arms by combining first 12 weeks in arm A and crossover
period in arm B (off-ART), and similarly in arms C and D.
The protocol was approved by each site’s institutional review board. Written informed consent was obtained from all
participants. The study was conducted according to human
experimentation guidelines of the U.S. Department of Health
and Human Services and was monitored by a study monitoring
committee of the AIDS Clinical Trial Group (NCT 01266616).
Evaluation of participants and follow-up

After screening and baseline evaluations were completed,
study participants had clinical and laboratory safety assess-
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ments at weeks 4, 10, 12, 16, 22, 24, and 28. Ophthalmologic
evaluations were performed at screening and at weeks 12 and
24; audiometric examinations were done as needed. Plasma
levels of HIV-1 RNA and CD4 and CD8 T lymphocyte
counts and other immunologic assays were performed at
screening, study entry, and weeks 10, 12, 22, 24 (also 14 days
before entry, for immunologic assays).
Immunologic evaluations
Flow cytometry. Cryopreserved peripheral blood mononuclear cells were thawed and stained with fluorochromelabeled monoclonal antibodies (Becton Dickinson [BD]) and
examined for expression of CD38 and HLA-DR on CD4 and
CD8 T cells in cohort 1 and were examined using a BD
FACSCalibur flow cytometer in cohort 1 and a BD LSR II
instrument in cohort 2. For both cohorts, viable lymphocyte
subpopulations were identified by staining with fluorochromelabeled antibodies targeting CD45RA, CCR7, CD127, and
PD-1. Intracellular expression of Bcl-2 and Ki-67 was also
examined after permeabilization. Gates were established using
fluorochrome-labeled isotype control antibodies and indices
were monitored using a BD LSR II flow cytometer and analyzed with BD FACSDiva software.
Dendritic cells (DCs) were identified as lineage negative,
HLA-DR positive, and by either CD123 or CD11c (all antibodies from BD Biosciences). DCs were also characterized for expression of co-stimulatory molecules CD83,
CD80, CD86 (BD Biosciences), and the negative regulator
PDL-1 (eBioscience). For cohort 2, antibodies recognizing
CCR7 (BD Biosciences) and ILT-7 (eBioscience) were
added to the staining panel. Fluorescence Minus One controls were used to define positivity of the DC marker antigens. Cells were analyzed on a BD LSR II flow cytometer
using FACSDiva software.
Plasma assays. Levels of IL-6, soluble CD14 (sCD14),
tumor necrosis factor receptor type 1, and interferon gammainduced protein 10 (IP10) in EDTA-anticoagulated plasma
were measured using Quantikine ELISA kits (R&D Systems). Levels of d-dimers were measured using the Asserachrom D-Di immunoassay (Diagnostica Stago). Plasma
levels of lipopolysaccharides (LPS) were quantified using the
Limulus Amebocyte Lysate (LAL) assay (QCL-1000; Lonza) per the manufacturer’s instructions.
For cohort 1, plasma samples were analyzed for IFNa and
IFNb levels by ELISA, and IFNa bioactivity (ELISA and iLite
kits, PBL Interferon Source) per the manufacturer’s directions.
Microarray assays. RNA extraction, and microarray
analysis were conducted at the Yerkes NHP Genomics Core
Laboratory (www.yerkes.emory.edu/nhp_genomics_core/).
Whole blood was collected into RNA PAXgene tubes
(QIAGEN) and purified and assessed as previously described.24 RNA was processed using the Affymetrix IVT
Express Kit25 and hybridized to Human Genome U133 Plus
2.0 arrays (Affymetrix). Baseline and week 12 samples from
10 chloroquine-treated and 10 placebo participants were run
blinded in cohort 1 and separately in cohort 2.
Microarray data were submitted to the GEO database according to MIAME standards. The accession numbers are
Series GSE71065; off-ART dataset GSE71063; and on-ART
dataset GSE71064.
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Statistical methods

The primary end point was the week 12 change from
baseline in percentage of CD8 T cells expressing HLA-DR
and CD38. For the immunologic end points, baseline was
computed as the mean of the pre-entry and entry values, and
the ‘‘week 12’’ value as the mean of the values at weeks 10
and 12. The primary analysis excluded subjects who discontinued study treatment for ‡14 days and (1) started ART
(off-ART arms) or (2) stopped ART or had HIV virological
rebound (on-ART arms); otherwise, an as-treated approach
was taken. Quantitative measures between arms were compared using Wilcoxon rank sum tests. Significant changes
from baseline were assessed using sign tests. Spearman’s
rank correlation (rho) tests were used to measure associations
between two measures. Two-sided tests were performed using a 5% level of significance for all but microarray analyses,
and no adjustments were made for multiple testing.
Microarray data analysis. Microarray data were preprocessed and normalized using RMA in the bioconductor limma package.26 One chloroquine-treated participant in the onART cohort was found to be an outlier and was excluded from
downstream analyses. To identify differentially expressed genes,
a paired t-test was used on the paired baseline and week 12
samples from each participant in the chloroquine treatment arm
of each cohort, with a gene-filtering criterion of an unadjusted p
value of p = .01 (Supplementary Tables S1 and S2; Supplementary Data are available online at www.liebertpub.com/aid).
Gene Set Enrichment Analysis (GSEA) was used to detect
significantly enriched pathways (www.broadinstitute.org/
gsea/index.jsp), in which pathways with a nominal p-value
of <.05 were considered significantly enriched. We chose
genes to focus further analyses based on the following criteria
(1) they were determined to be statistically differentially
expressed based on the paired t-test described above (2) the
collective genes in a pathway were determined to be significantly enriched by GSEA, or (3) we also ran analyses on genes
know to be affected by chloroquine treatment (interferonstimulated genes [ISGs]) or known markers of HIV-associated
immune activation (MKI67, CCR5, and HLA-DR).
Results
Study population

Between March 2009 and July 2010, 33 study participants were enrolled into cohort 1; between December 2010 and
November 2012, 37 study participants were enrolled into cohort 2. In the off-ART cohort 1, 16 participants were randomized to arm A and 17, to arm B. In the on-ART cohort 2, 18 and
19 were randomized to arms C and D, respectively (Table 1).
In the off-ART cohort, 6 of the 33 participants (3 in arm A,
3 in arm B) who started study treatment discontinued study
treatment prematurely. In the on-ART cohort, 3 (all from arm
C) discontinued prematurely. None of the study treatment
discontinuations was related to study treatment-related adverse events. None of the ART-treated participants interrupted ART during the study.
Safety

No adverse events attributable to the study treatment occurred. There were no opportunistic infections or death. One
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episode of pneumonia in arm C occurred during treatment
with chloroquine.
Immunologic evaluations

In the off-ART cohort, 31 participants qualified for the
analyses of the first 12 weeks of the study; 28 participants
were included in the analyses of changes after 12 weeks of
chloroquine treatment in both arms (before or after crossover). In the on-ART cohort, 35 and 34 participants were
included in these analyses, respectively.
Cellular immune activation markers in off-ART cohort. The
median week-12 decrease from baseline CD8 T-cell activation (% HLA-DR and CD38+) was larger in arm A (chloroquine) than in arm B (placebo), but not significantly (-2.0%
vs. -0.5%, p = .428, Table 2 and Fig. 1). There was not a
significant week 12 change from baseline in arm A. Combining the changes after 12 weeks of chloroquine in both
arms also showed no significant change. Similarly, no significant change from baseline in the percentage of CD4 T
cells expressing HLA-DR and CD38 was seen after 12 weeks
of chloroquine.
Plasma HIV RNA changes and relationship to cellular
immune activation markers in the Off-ART cohort. There

was a significant increase from baseline in plasma HIV-1
RNA in arm A after 12 weeks of chloroquine (median
0.29 log10 increase, p < .001) that was greater than the change
in the placebo arm B (median 0.20 log10 decrease, p = .077);
the difference between the arms was statistically significant
( p < .001, Table 2). The combined changes in both arms after
12 weeks of chloroquine also showed a significant increase
from baselines (median 0.30 log10HIV-1 RNA, p < .001).
HIV RNA levels fell 12 weeks after stopping chloroquine
(arm A) back to levels not significantly different from baseline ( p = .388).
Combining data from both arms yielded a significant
positive association between changes in log10HIV-1 RNA
and the proportion of CD8 T cells expressing HLA-DR and
CD38 (rho = 0.485, p = .009). Thus, we suspected that the
increase in HIV levels as a result of chloroquine use may have
confounded any effect of chloroquine on immune activation
in the off-ART cohort.
Cellular immune activation markers in the on-ART
cohort. There was a trend of a week 12 decrease from

baseline in the proportions of CD8 T cells expressing HLADR and CD38 in arm C during chloroquine treatment (median -3.1%, p = .077). The week-12 changes from baseline
were not significantly different between arms C and D
( p = .247, Table 2 and Fig. 1). Combining the changes in the
proportion of CD8 T cells expressing HLA-DR and CD38
after 12 weeks of chloroquine treatment in both arms showed
a significant decrease in CD8 T-cell activation (median decrease = 3.0%, p = .003). A separate analysis within arm D
gave similar results (median decrease = 2.9% during chloroquine treatment, p = .031).
No significant change from baseline occurred in the percentage of CD4 T cells expressing HLA-DR and CD38 after
12 weeks of chloroquine (arm C). Although there was a significant decrease from baseline at week 12 in this percentage
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Table 1. Baseline Demographics
Off-ART cohort
Characteristic

Total (N = 70)

Age (in years)
Median (Q1, Q3)
46 (36, 50)
18–29
8 (11%)
30–39
16 (23%)
40–49
25 (36%)
50–59
18 (26%)
60–69
2 (3%)
70–79
1 (1%)
Gender
Male
63 (90%)
Female
7 (10%)
Race/Ethnicity
White non-Hispanic
39 (56%)
Black non-Hispanic
28 (40%)
Hispanic (regardless
3 (4%)
of race)
Baseline CD4 count (cells/mm3)
Median (Q1, Q3)
386 (260, 541)
Baseline CD8 count (cells/mm3)
Median (Q1, Q3)
740 (540, 1,094)
Entry HIV-1 RNA
£LLQ
33 (47%)
>LLQ
37 (53%)
Entry log10 HIV-1 RNA (copies/ml)
Median (Q1, Q3)
4.46 (4.03, 4.75)a

Arm A (N = 16)
35
5
5
5
1
0
0

(29, 43)
(31%)
(31%)
(31%)
(6%)
(0%)
(0%)

On-ART cohort
Arm B (N = 17)
39
2
7
8
0
0
0

(35, 44)
(12%)
(41%)
(47%)
(0%)
(0%)
(0%)

Arm C (N = 18)
50
1
1
5
10
0
1

(48, 55)
(6%)
(6%)
(28%)
(56%)
(0%)
(6%)

Arm D (N = 19)
49
0
3
7
7
2
0

(41, 56)
(0%)
(16%)
(37%)
(37%)
(11%)
(0%)

14 (88%)
2 (13%)

15 (88%)
2 (12%)

17 (94%)
1 (6%)

17 (89%)
2 (11%)

9 (56%)
7 (44%)
0 (0%)

11 (65%)
5 (29%)
1 (6%)

9 (50%)
8 (44%)
1 (6%)

10 (53%)
8 (42%)
1 (5%)

641 (561, 755)
920 (632, 1,108)
0 (0%)
16 (100%)

493 (448, 541)

259 (224, 281)

270 (218, 296)

1,083 (737, 1,260)

640 (454, 985)

656 (414, 842)

0 (0%)
17 (100%)

4.48 (4.02, 4.74)

4.42 (4.03, 4.83)

16 (89%)
2 (11%)

17 (89%)
2 (11%)

N/Ab

N/Ab

a

Arms A and B only (N = 33).
HIV-1 RNA values of 30 and 48 copies (LLQ = 20), 129 (LLQ = 40), and 75 (LLQ = 50).
ART, antiretroviral therapy; LLQ, lower limit of quantification.
b

within arm C ( p = .021), changes were not significantly different between the two arms ( p = .107, Table 2). There were no
significant changes in either the percentage of CD4 T cells
expressing HLA-DR and CD38 ( p = .121) or the percentage of
CD4 T cells expressing CD38 ( p = 1.000) after 12 weeks of
chloroquine in both arms combined, but there was a significant
change in the proportion of CD4+ T cells expressing HLA-DR
(median decrease of 1.5%, p = .003).
CD4 T-cell counts. There were no significant changes
from baseline in CD4 T-cell counts after 12 weeks of chloroquine in either arm A (off-ART) or arm C (on-ART) and no
significant differences in the changes between the chloroquine arm and the placebo arm in either cohort (Table 2).
Combining the changes in CD4 T-cell count after 12 weeks of
chloroquine in both arms in each cohort indicated a significant median decrease in each during chloroquine administration (off-ART: -39 cells/mm3, p = .036; on-ART: -15
cells/mm3, p = .024).
T-cell memory subsets. Among the markers measured on

CD4 and CD8 central memory T cells, arm A (off-ART) and
the combined off-ART arms showed a significant median
decrease after 12 weeks of chloroquine in the proportions of
CD4+ cells expressing the IL-7 receptor alpha chain, CD127
(-1.55%, p = .035, Table 2; -1.18%, p = .036, respectively).
The chloroquine arm in both cohorts showed no significant
changes in any of the myeloid DC (mDC) and plasmacytoid

DC (pDC) markers measured (Table 2). Combined data
from both arms after 12 weeks of chloroquine showed a
significant median change from baseline only in the proportion of pDCs expressing CD83 in the on-ART cohort (median
decrease = 2.52%, p = .009).
Cytokines and soluble activation markers. Of the cytokines and soluble activation markers measured, arm A
(chloroquine) in the off-ART cohort showed a significant
week 12 median change only in LPS (+3.14 pg/ml, p = .013)
levels. There was a trend toward a decrease in IP10 after
12 weeks of chloroquine treatment in the on-ART arm C
(-20.6 pg/ml, p = .057). The differences between the two
arms within either cohort in week 12 changes from baseline
in all markers were not significant ( p > .05, Table 2). When
both arms within each cohort were combined, after 12 weeks
of chloroquine there was a significant median change only in
IP10 in the on-ART cohort (-12.77 pg/ml, p = .011).
Microarray analyses
Off-ART cohort (arms A and B). The effect of chloroquine on the blood transcriptome was modest, and a low
number of differentially expressed genes was observed.
Nevertheless, a handful of genes were downregulated after
chloroquine treatment beyond the technical and clinical
variability predicted by the placebo analysis (Fig. 2A).
Manual inspection, volcano plots, and hierarchical clustering of the top 1,000 genes with the highest variance after
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+

+

CD8 /HLA-DR /CD38 %
CD8+/CD38+ %
CD8+/HLA-DR+ %
CD4+/HLA-DR+/CD38+ %
CD4+/CD38+ %
CD4+/HLA-DR+ %
CD8+ count (cells/mm3)
CD8+ %
CD4+ count (cells/mm3)
CD4+ %
Log10 HIV-1 RNA (c/ml)
Central memory
CD8+ CM%
CD8+ CM Bcl2+%
CD8+ CM ki-67+ %
CD8+ CM Bcl2+/ki-67+ %
CD8+ CM CD127+ %
CD8+ CM PD-1+ %
CD8+ CM CD127+/PD-1+ %
CD4+ CM%
CD4+ CM Bcl2+ %
CD4+ CM ki-67+ %
CD4+ CM Bcl2+/ki-67+ %
CD4+ CM CD127+ %
CD4+ CM PD-1+ %
CD4+ CM CD127+/PD-1+ %
Dendritic cells
% mDC of total DCs
% mDC of total viable singlets
% mDC CD80+
% mDC CD83+

+

Week 12 change from baseline

(-0.10, 0.60)
(-1.15, 3.50)
(-0.25, 2.55)
(-0.20, 1.55)
(-8.20, 0.85)
(-5.65, 7.35)
(-6.50, 3.10)
(-2.05, 2.15)
(-0.60, 1.80)
(0.00, 0.40)
(-0.30, 0.35)
(-4.15, -0.05)
(-2.50, 6.35)
(-3.45, 3.30)
(-1.23, 7.70)
(-0.003, 0.647)
(-0.73, 0.28)
(-6.21, 8.44)

5.25
0.14
0.10
5.78

(-10.0, 9.0)
(-9.5, 3.5)
(-9.0, 8.0)
(-3.0, 1.5)
(-6.0, 4.0)
(-3.0, 1.0)
(-83, 43)
(-1.0, 2.5)
(-150, 4)
(-2.0, 0.5)
(0.15, 0.35)

0.10
-0.58
0.15
-0.05
-3.20
1.75
-0.60
0.40
-0.25
0.25
0.02
-1.55
-0.15
-0.65

-2.0
0.0
-3.5
0.0
1.0
0.0
-36
2.0
-27
0.0
0.29

Arm A

(-4.78, 2.18)
(-0.076, 0.076)
(0.01, 0.70)
(-5.61, 10.36)

-1.68
-0.004
0.30
3.26

0.48)
2.15)
1.17)
0.73)
5.38)
1.98)
4.18)
3.27)
1.35)
0.60)
0.43)
2.20)
2.38)
1.85)

(-0.13,
(-1.10,
(-1.02,
(-0.02,
(-5.43,
(-5.25,
(-3.80,
(-0.75,
(-0.55,
(-0.65,
(-0.40,
(-2.85,
(-4.60,
(-3.45,

(-2.3, 2.8)
(-2.0, 2.0)
(-1.5, 3.5)
(-1.8, 3.0)
(-2.8, 2.5)
(-1.8, 2.8)
(-120, 86)
(-1.3, 1.3)
(-38, 71)
(0.0, 1.5)
(-0.27, -0.02)

Arm B

0.10
0.62
0.05
0.30
0.63
-3.05
0.53
1.20
-0.20
-0.40
-0.05
0.95
-1.15
-0.65

-0.5
0.3
1.8
0.5
0.5
0.0
3
-0.3
-11
1.0
-0.20

Off-ART cohort

.060
.033
.045
.740

.868
.735
.394
.814
.277
.440
.464
.572
.629
.382
.782
.160
.281
.830

.428
.961
.313
.428
.946
.500
.740
.080
.206
.035
<.001

p*

1.14
-0.01
0.27
-11.30

0.38
0.04
-0.07
-0.09
0.96
-1.28
-0.37
-0.05
-0.48
-0.29
-0.15
0.74
-0.48
0.34

-3.1
-0.8
-3.1
-0.9
-0.6
-1.6
-18
0.5
-6
1.0

Table 2. Immunologic and Virological End Points

(-4.02, 7.40)
(-0.09, 0.10)
(-0.37, 0.55)
(-21.47, 16.78)

(-0.05, 0.95)
(-1.98, 1.20)
(-0.37, 0.30)
(-0.30, 0.29)
(0.22, 3.63)
(-4.31, 0.94)
(-2.34, 1.61)
(-4.50, 1.90)
(-3.03, 1.23)
(-0.61, 0.56)
(-0.57, 0.30)
(-1.74, 4.06)
(-3.72, 2.24)
(-1.30, 3.34)

(-4.3, 0.4)
(-3.7, 3.3)
(-6.9, -1.0)
(-2.1, 0.0)
(-2.4, 2.3)
(-3.5, -0.5)
(-67, 6)
(-1.0, 1.8)
(-21, 10)
(-1.0, 1.0)
N/A

Arm C

0.47
-0.02
-0.07
-3.02

0.10
0.01
0.12
0.06
0.41
0.01
0.26
-0.65
0.36
0.03
-0.28
0.06
-0.39
-0.95

-1.2
-2.5
-1.4
-0.1
-1.1
-0.5
19
-0.3
7
-0.2

On-ART cohort

(-5.37,
(-0.12,
(-0.34,
(-6.55,

(-0.35,
(-1.52,
(-0.49,
(-0.49,
(-1.86,
(-2.97,
(-3.53,
(-3.00,
(-3.00,
(-0.50,
(-0.50,
(-3.36,
(-5.05,
(-4.23,

3.72)
0.04)
0.30)
6.33)

0.40)
1.33)
0.45)
0.38)
1.80)
2.23)
2.22)
1.25)
1.03)
0.66)
0.29)
1.30)
0.93)
1.12)

(-3.3, 1.4)
(-4.5, 4.2)
(-4.6, 0.2)
(-1.8, 0.6)
(-3.1, 1.4)
(-2.4, 1.4)
(-39, 66)
(-1.0, 1.0)
(-17, 23)
(-2.0, 0.5)
N/A

Arm D

(continued)

.523
.589
.317
.461

.282
.756
.935
.731
.321
.843
.957
.767
.589
.832
.935
.627
.304
.358

.247
.800
.093
.436
.876
.107
.208
.567
.247
.418
N/A

p*
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0.18
3.14
0.00
0.02
-9.72
-58.85
0.02
28.29

(-0.18, 0.57)
(0.32, 12.33)
(0.00, 0.00)
(-0.12, 0.28)
(-74.37, 55.89)
(-79.25, 28.21)
(-0.13, 0.21)
(-65.86, 61.66)

0.63 (-1.78, 4.08)
-0.24 (-1.42, 1.30)
-4.55 (-6.03, -0.95)
0.02 (-0.02, 0.21)
-0.004 (-0.05, 0.00)
0.05 (-11.20, 13.61)
-1.09 (-2.49, 0.50)
-0.36, -0.86, 0.73)

Arm A

0.11
0.00
0.00
-0.03
-9.98
-56.37
-0.06
6.45

-0.82
1.79
2.35
-0.01
0.001
1.21
0.08
-0.17
(-0.07, 0.60)
(-0.86, 7.23)
(-0.06, 0.00)
(-0.08, 0.00)
(-28.32, 32.62)
(-173.40, 146.95)
(-0.23, 0.25)
(-45.61, 72.65)

(-2.26, 0.58)
(-2.27, 7.63)
(-3.04, 4.60)
(-0.05, 0.09)
(0.000, 0.053)
(-10.28, 6.45)
(-1.14, 0.83)
(-1.28, 2.22)

Arm B

.953
.173
.752
.056
.861
.599
.520
.892

.220
.299
.064
.453
.056
.984
.446
.892

p*

(-2.78, 0.90)
(-0.80, 2.64)
(-7.40, 4.02)
(-0.06, 0.06)
(-0.07, 0.08)
(-14.59, 0.53)
(-3.40, 4.04)
(-2.92, 1.57)

Arm C

(-3.25, 1.90)
(-1.30, 3.38)
(-3.72, 5.37)
(-0.05, 0.07)
(-0.05, 0.14)
(-11.36, 2.43)
(-2.35, 3.84)
(-1.17, 2.86)

Arm D

0.01 (-0.40, 0.48)
0.25 (0.00, 1.50)
Assay not done
Assay not done
-8.68 (-21.31, 12.76)
55.57 (-58.84, 138.36)
0.03 (-0.09, 0.10)
6.92 (-3.63, 17.46)

0.14
-0.42
-0.47
0.01
-0.001
-0.23
0.75
-0.13

On-ART cohort

0.08 (-0.43, 0.30)
0.00 (-3.50, 1.00)
Assay not done
Assay not done
-20.60 (-42.43, -6.10)
3.42 (-256.99, 57.07)
0.03 (-0.11, 0.13)
17.01 (-0.57, 50.92)

-0.86
0.63
-1.14
-0.01
0.003
-4.95
0.91
0.08

*Wilcoxon rank sum test p values to compare chloroquine and placebo arms within each cohort.
CM, central memory; DC, dendritic cells; IL, interleukin; LPS, lipopolysaccharides; mDC, myeloid DC; pDC, plasmacytoid DC.

% mDC CD86
% mDC PDL-1+
% pDC of total DCs
% pDC of total viable singlets
% pDC CD80+
% pDC CD83+
% pDC CD86+
% pDC PDL-1+
Cytokines
IL-6 (pg/ml)
LPS (pg/ml)
Type I IFN (U/ml)
IFN-Beta (pg/ml)
IFN-Gamma IP-10 (pg/ml)
sTNFr-I (pg/ml)
sCD14 (million pg/ml)
d-Dimer (ng/ml)

+

Week 12 change from baseline

Off-ART cohort

Table 2. (Continued)

.779
.095
N/A
N/A
.168
.125
.866
.283

.731
.832
.523
.446
.838
.523
.781
.756

p*
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FIG. 1. CD8+/HLA-DR+/CD38+ %
for off-ART (arms A and B) and onART (arms C and D) cohorts at study
weeks. Connected bold filled symbols
represent median, and the bars represent interquartile ranges. Arms A and
C received chloroquine for the first 12
weeks, then placebo. Arms B and D
received placebo for the first 12
weeks, then chloroquine. The number
of participants varied over the study
weeks, due to missed visits or inadequate samples. ART, antiretroviral
therapy.

chloroquine treatment showed that the majority of the
downregulated genes were ISGs. Five of 10 (50%) of the
chloroquine-treated participants had marked downregulation
of ISGs compared to none in the control group (Fig. 2B and
Supplementary Table S1).
Of genes reflecting immune activation, CD38 (-1.198fold change; p = .0003) and CCR5 (-1.15 average fold
change, p < .001) were moderately but significantly reduced
in 10/10 participants (Fig. 2A, D). In contrast, expression of
these genes in the placebo-treated participants was randomly distributed.
We also compared the week 12 chloroquine and placebo
data sets for signatures of ISGs and immune activation using
gene-set enrichment analysis with gene sets we had established previously using primary data27; we found a strong and
statistically significant enrichment of both pathways in the
placebo group, with lowered expression of these pathways in
the chloroquine group (Fig. 2E). This complementary analysis strategy provided additional evidence that chloroquine
had a suppressive effect on ISG and immune activation gene
expression in the off-ART cohort.

On-ART cohort (arms C and D). A large number of genes
associated with the 60S (ribosomal L proteins, RPL genes)
and 40S (ribosomal S proteins, RPS genes) subunits, 72 probe
sets representing 40 unique RPL genes and 32 probe sets (20
unique genes) of RPS genes, were downregulated after
chloroquine treatment. None of these probe sets was downmodulated after placebo administration. In contrast to our
observations in the off-ART cohort, we did not observe any
effect of chloroquine on expression of classical immune activation marker genes (MKI67, CD38, or HLA-DR), although
there was strong downregulation of CD6, which has been
considered a putative co-stimulatory molecule on T cells
(Fig. 3A, B and Supplementary Table S2).28
Discussion

In this randomized, double-blind, placebo-controlled,
crossover study, chloroquine modestly reduced immune activation in ART-treated HIV-infected participants. The primary
analyses compared the changes across treatment arms in the
proportion of CD8 T cells co-expressing CD38 and HLA-DR
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FIG. 2. Transcriptome response in whole blood to chloroquine treatment in therapy-naı̈ve (off-ART) HIV-infected
participants. RNA from whole blood was obtained before treatment and after 12 weeks of chloroquine or placebo administration and was hybridized to human Affymetrix arrays. Differential expression was assessed using paired t-tests of the
chloroquine and placebo data sets independently. (A) Volcano plots showing distribution of fold-changes (x-axis) compared
to paired t-test p-values (y-axis) of all genes on the array. Red dots on the upper panel indicate probe sets specific for ISGs.
(B) Two-way hierarchical clustering of 1,000 genes exhibiting most variance in the chloroquine-treated participants. The
color scale is shown at the bottom of the panel; ratios are relative to pretreatment samples. (C) Two-way clustering and heat
map of ISGs. Each column represents individual participants. The color scale is shown at the bottom of the panel; ratios are
relative to pretreatment samples. (D) Plot of fold-changes for individual participants, for select immune activation genes.
Data points depict the log ratio of fold-changes for individual participants; bars indicate means. (E) Gene set enrichment
plots depicting enrichment testing of ISGs and immune activation gene sets defined in studies of simian immunodeficiency
virus infection (details in the Materials and Methods section). The microarray data from week 12 postchloroquine treatment
samples were directly compared to data from week 12 placebo treatment; the x-axis depicts the ranking of nonredundant,
annotated genes contained on the array according their signal-to-noise ratio; genes were ranked from those upregulated in
the chloroquine-treated samples on the left to those upregulated in placebo samples on the right. Individual genes from each
gene set are depicted by both dots and vertical lines at the bottom. Genes in the leading edge that contribute most
significantly to the enrichment are depicted in red. The significance of the enrichment statistic is shown in the upper right
quadrant. ISGs, interferon-stimulated genes.

644

JACOBSON ET AL.

FIG. 3. Gene expression
profiling of clinical response
to chloroquine treatment in
HIV-infected participants receiving ART (on-ART). Microarray analysis was conducted
as described in Figure 2 on
RNA from whole blood samples collected at pretreatment
and after 12 weeks of chloroquine or placebo. Significance of statistical differential
expression induced by the 12week treatment phase was
tested by performing paired
t-tests separately for the chloroquine and placebo data sets.
(A) Volcano plots depicting
fold-changes (x-axis) versus
paired t-test p-values (y-axis)
of all genes on the array. Red
dots depict probe sets specific
for ISGs. (B) Breakout expression plots of gene families
with differential expression
after 12 weeks of chloroquine
treatment.

in the first 12 weeks before crossover, but the crossover design
provided greater statistical power in secondary analyses. When
the periods of chloroquine use before and after crossover in
both arms of the on-ART study were combined, there was a
significant reduction in the proportions of CD8 T cells coexpressing CD38 and HLA-DR and in CD4 T cells expressing
HLA-DR. The effect was modest, however, representing only
a reduction of 3% in the percentage of activated CD8 T cells.
Furthermore, no consistent effect on soluble markers of inflammation was observed, and these markers have a stronger
association with clinical outcomes in patients on ART than do
cellular markers of immune activation.11,29
Any effect on immune activation in the off-ART study was
confounded by enhancement of viral replication by chloroquine, which itself may have driven greater immune activation
as suggested by a significant correlation between changes
in plasma viremia and CD8 T-cell activation. Assessment in
the on-ART cohort removed HIV replication as a potentially

confounding driver of activation, although it is possible that
chloroquine could have induced low-level viral replication,
only detectable by single copy assay, in this cohort.
Transcriptional analyses revealed that approximately half
of those receiving chloroquine in the off-ART cohort had
decreased expression of ISGs, despite an increase in plasma
viremia. Typically, ISG expression increases with HIV-1
replication. We have observed in the nonhuman primate
model after depletion of CD8 T cells that even modest
(0.5 log) increases in viremia increase ISG expression.30 It is
interesting that, in this study, we observed an ‘‘uncoupling’’
of ISG expression and plasma viremia. We also observed a
modest but consistent decrease in CD38 and CCR5 RNAs. In
the on-ART cohort, no effect of chloroquine on genes associated with immune activation was discerned, but suppressive ART appeared to unmask a suppressive effect of
chloroquine on genes encoding proteins associated with the
40 S and 60 S ribosomal subunits. The significance of this
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finding is unclear, but it could indicate that chloroquine influences ribosomal activity and the control of gene expression
at the translation step.
Although earlier studies found a reduction in or no effect on
viremia during chloroquine or hydrochloroquine administration,31–33 a modest increase was seen in one controlled trial
of hydroxychloroquine in persons off ART.34 Similar increases in plasma HIV levels had been seen in earlier studies of
immunosuppressive agents: cyclosporine A,35 prednisone,36
and thalidomide37 in untreated HIV infection.
The mechanism whereby chloroquine enhances HIV replication is unclear. Conceivably, blockade of TLR7/TLR8
signaling may limit induction of host antiviral defenses such
as those mediated by type 1 interferons. Alternatively, the
effect on plasma viremia could have been the result of a direct
enhancement of infectivity by chloroquine, a finding in some
in vitro studies,38,39 while others have shown chloroquine to
inhibit HIV replication.40,41
Other researchers have assessed the effects of chloroquine or
hydroxychloroquine, a related compound, on immune activation in HIV-infected participants. One small study among
participants not receiving ART reported a reduction in the
frequency of CD38+HLA-DR+CD8 T cells and Ki-67 expression in both CD8 and CD4 T cells after 2 months of chloroquine treatment (six participants received 250 mg/day, three
received 500 mg/day) that was not seen in the three placebo
recipients.42 Two earlier randomized controlled trials using
hydroxychloroquine 800 mg/day (bioequivalent to 500 mg/day
of chloroquine) found reduced plasma levels of IL-6, but not
IL-1a, IL-1b, or TNF-a, after 8 weeks of treatment.31,32 In
comparison, a randomized, double-blind, placebo-controlled
study of 48 weeks of hydroxychloroquine 400 mg/day in 83
participants not receiving ART found no effect on the frequency of CD38+HLA-DR+CD8 T cells or CD38+HLADR+CD4 T cells, or on Ki67 expression in CD8 or CD4 T cells,
or on plasma levels of inflammatory cytokines or d-dimers.34
In an open-label study, administering hydroxychloroquine
400 mg/day for 6 months to 20 ART-treated participants led
to a nonsignificant decrease in the frequency of CD38+HLADR+CD8 T cells. CD4 T-cell cycling (Ki67) and monocyte
activation (CD69) fell. T regulatory cells increased; an increased pDC population produced less interferon-a; and
plasma levels of LPS, IL-6, and TNF-a fell.43 Another uncontrolled study of chloroquine 250 mg/day for 24 weeks in
19 ART-treated participants found no reduction in T-cell
activation, the frequency of pDCs; or plasma levels of ddimer, C-reactive protein, or inflammatory cytokines.44
CD4 T-cell counts decreased slightly with chloroquine use
in our study. The decline was lower in participants receiving
ART (-15 vs. -39 cells/mm3, combining chloroquine periods
across cohort arms), suggesting that at least some of the decrease might have been the result of enhanced viral replication
whereas decreases in the on-ART arm might reflect other effects of the drug. One recent study of chloroquine treatment
in ART-naı̈ve participants reported an additional decline of
CD4 T cells of 62 cells/mm3 relative to the placebo group,32
whereas a second study of therapy-naı̈ve chloroquine treatment
reported no effect on CD4 T-cell levels.42 Whether this effect
of chloroquine on CD4 T cell counts would persist or increase
over time and place persons at risk for morbidity is unknown.
In summary, short-term administration of chloroquine
250 mg/day to persons with chronic HIV infection, treated or
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not with ART, had only modest effects on cellular indices of
immune activation, activities unlikely to elicit substantial
clinical benefit. It is conceivable that higher doses of chloroquine would have greater activity in this regard, but might
also be more toxic.45 In those not receiving ART, HIV RNA
levels in plasma rose during chloroquine administration,
likely reflecting the adverse effects of immune suppression
on viral control. Our results suggest that chloroquine and
related agents are not likely to confer meaningful clinical
benefit in HIV infection. It remains to be seen in treated HIV
infection, where immune activation, coagulation, and inflammation have been linked to morbid outcomes, whether
other interventions that can attenuate these indices are associated with lower risks of morbid events.
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